Skip to content

Author

G. Tomaras

We have 6 of 543 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections

The two parallel Antibody Mediated Prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here we analyzed HIV-1 acquisition in AMP through the Week 104 final study visit. Against viruses considered...

A. deCamp, M. Juraska, Li Li et al. · 0 citations
Open access Oct 2026

Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans

Inducing a broadly neutralizing antibody (bnAb) response is a key goal of HIV-1 vaccine development. Despite significant progress, it is unknown whether vaccine-primed B cells can be reactivated and matured to secrete bona fide bnAbs. In the IAVI C107/C110 single-arm, open-label human trial, VRC01-class memory B cells...

T. Caniels, Madhu S. Prabhakaran, S. Agrawal et al. · 0 citations
Open access Sep 2026

mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study

CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity, and in people with HIV and hybrid immunity, CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.

Sharon Khuzwayo, Bo Zhang, Valentin Voillet et al. · 1 citation
Open access Oct 2026

Correlates of Protection and Response Durability of the RTS,S Vaccine in Four Malaria Challenge Studies

RTS,S/AS01 (RTS,S) is one of two WHO-recommended malaria vaccines for children in moderate-to-high transmission settings. Yet, no validated immune correlate of protection (CoP) has been established for this vaccine. We selected 16 biomarkers to further assess as candidate CoPs, based largely on their ability to well-pr...

S.-Y. Kim, T. Linnekin, L. Carpp et al. · 0 citations
Open access Sep 2026

Preferential engagement of the anti-inflammatory ATP/adenosine axis by HIV vaccine candidate with V1-deleted envelope in male rhesus macaques

Ex vivo, ΔV1 gp120 reduced CCR5 expression on CD4+ T cells relative to WT gp120, consistent with the anti-inflammatory mucosal response by ΔV1-vaccine regimens in vivo, promotes an anti-inflammatory mucosal landscape less permissive to HIV seeding and dissemination following virus exposure.

Isabela Silva de Castro, Mohammad Arif Rahman, Massimiliano Bissa et al. · 0 citations
Open access Jul 2026

Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates

A modified HIV-1 vaccine regimen incorporating next-generation adjuvants to improve immune responses and vaccine efficacy in a gold standard, pre-clinical primate model indicated that novel adjuvants represent a promising strategy for improving immune responses to protein immunogens.

Hannah A. D. King, C. Subra, Emily Tourtellott et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.